Experimental cell therapy tested in 3 ALS patients
NCT ID NCT03241784
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested whether infusing a patient's own regulatory T cells (immune-calming cells) along with interleukin-2 injections is safe for people with ALS. Only 3 participants were enrolled, and the main goal was to check for side effects. The approach aims to slow disease progression by reducing immune system attacks on nerve cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
T-regulatory cells and interleukin-2 (IL-2)
What this could lead to
If successful, this could point toward a way to slow ALS progression by calming the immune system.
What could go wrong
This is a very early, tiny phase 1 safety trial with only 3 participants. It cannot prove effectiveness, and side effects or lack of benefit are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS (AMYOTROPHIC LATERAL SCLEROSIS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Methodist Neurological Institute
Houston, Texas, 77030, United States